Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

Summary

This is a proof of concept, single center study for the donation of HCV-positive hearts to HCV negative recipient patients, with preemptive, interventional treatment with 12-16 weeks of grazoprevir and elbasvir (with or without ribavirin) to prevent HCV transmission upon transplantation.

Timeline

Start

2018-08-01

Primary completion

2020-12-31

Completion

2021-06-30

Outcome

Outcome not reported

Stopped: “moved forward with another protocol utilizing pan genotypic treatment once it became commercially available and FDA approved”

Drugs

Indications